Age-grouped differences in adverse drug events from psychotropic medication

Research output: Contribution to journalArticle

Abstract

Objective: This review aims to detail specific psychotropic medication treatment differences in adverse drug events (ADEs) between children, adolescents, and adults. Method: A thorough data-based search of ADEs was made, augmented by findings from approved and updated U.S. Food and Drug Administration (FDA) drug labels, controlled clinical trial reports, and from FDA information on ADEs at scheduled public hearings. Results: Children were found to generally exhibit more ADEs to psychotropic medication than adolescents and adults. These ADEs primarily include altered growth velocity, rash, vomiting, dystonia, tics, affect lability, activation, metabolic blood test abnormalities, sedation, sialorrhea, and electrocardiogram irregularities. Conclusion: Children have more biological vulnerabilities than older individuals, which could account for their greater rate of ADEs to psychotropic medication treatment.

Original languageEnglish (US)
Pages (from-to)299-309
Number of pages11
JournalJournal of Child and Adolescent Psychopharmacology
Volume21
Issue number4
DOIs
StatePublished - Aug 1 2011

Fingerprint

Drug-Related Side Effects and Adverse Reactions
United States Food and Drug Administration
Sialorrhea
Tics
Dystonia
Controlled Clinical Trials
Hematologic Tests
Exanthema
Hearing
Vomiting
Electrocardiography
Therapeutics
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

Age-grouped differences in adverse drug events from psychotropic medication. / Safer, Daniel J.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 21, No. 4, 01.08.2011, p. 299-309.

Research output: Contribution to journalArticle

@article{dcfb9802c40b445abb33b3def584826e,
title = "Age-grouped differences in adverse drug events from psychotropic medication",
abstract = "Objective: This review aims to detail specific psychotropic medication treatment differences in adverse drug events (ADEs) between children, adolescents, and adults. Method: A thorough data-based search of ADEs was made, augmented by findings from approved and updated U.S. Food and Drug Administration (FDA) drug labels, controlled clinical trial reports, and from FDA information on ADEs at scheduled public hearings. Results: Children were found to generally exhibit more ADEs to psychotropic medication than adolescents and adults. These ADEs primarily include altered growth velocity, rash, vomiting, dystonia, tics, affect lability, activation, metabolic blood test abnormalities, sedation, sialorrhea, and electrocardiogram irregularities. Conclusion: Children have more biological vulnerabilities than older individuals, which could account for their greater rate of ADEs to psychotropic medication treatment.",
author = "Safer, {Daniel J.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1089/cap.2010.0152",
language = "English (US)",
volume = "21",
pages = "299--309",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Age-grouped differences in adverse drug events from psychotropic medication

AU - Safer, Daniel J.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Objective: This review aims to detail specific psychotropic medication treatment differences in adverse drug events (ADEs) between children, adolescents, and adults. Method: A thorough data-based search of ADEs was made, augmented by findings from approved and updated U.S. Food and Drug Administration (FDA) drug labels, controlled clinical trial reports, and from FDA information on ADEs at scheduled public hearings. Results: Children were found to generally exhibit more ADEs to psychotropic medication than adolescents and adults. These ADEs primarily include altered growth velocity, rash, vomiting, dystonia, tics, affect lability, activation, metabolic blood test abnormalities, sedation, sialorrhea, and electrocardiogram irregularities. Conclusion: Children have more biological vulnerabilities than older individuals, which could account for their greater rate of ADEs to psychotropic medication treatment.

AB - Objective: This review aims to detail specific psychotropic medication treatment differences in adverse drug events (ADEs) between children, adolescents, and adults. Method: A thorough data-based search of ADEs was made, augmented by findings from approved and updated U.S. Food and Drug Administration (FDA) drug labels, controlled clinical trial reports, and from FDA information on ADEs at scheduled public hearings. Results: Children were found to generally exhibit more ADEs to psychotropic medication than adolescents and adults. These ADEs primarily include altered growth velocity, rash, vomiting, dystonia, tics, affect lability, activation, metabolic blood test abnormalities, sedation, sialorrhea, and electrocardiogram irregularities. Conclusion: Children have more biological vulnerabilities than older individuals, which could account for their greater rate of ADEs to psychotropic medication treatment.

UR - http://www.scopus.com/inward/record.url?scp=80052099080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052099080&partnerID=8YFLogxK

U2 - 10.1089/cap.2010.0152

DO - 10.1089/cap.2010.0152

M3 - Article

C2 - 21851188

AN - SCOPUS:80052099080

VL - 21

SP - 299

EP - 309

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 4

ER -